Pixium Vision (FR0011950641 – PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, announces today that it has been awarded the¬†Prix¬†Galien 2018 in the “Research Project” category¬†for its PRIMA device for the treatment of dry¬†Age-related Macular Degeneration¬†(AMD).
Created as a “pharmaceutical research award” in France in 1970, the prestigious Prix Galien is recognised by the French authorities for its public interest and has an international reputation. Each year, the Prix Galien recognises the best healthcare innovations in five categories: pharmaceutical products, medical systems, e-health, patient care and research. The Prix Galien is awarded by a jury comprised of 50 international experts in healthcare. Their independence, authority and reputation confirm the excellence and credibility of the Galien Prize.